Gulf's First Robotic Lung Transplant Performed in Abu Dhabi
Jul 11, 2025
In a historic breakthrough for regional healthcare, Cleveland Clinic Abu Dhabi has become the first medical institution in the Gulf to perform a robotic lung transplant—making it just the fifth centre worldwide to do so.
The landmark procedure marks a major advancement in the region's surgical capabilities. Two patients with idiopathic pulmonary fibrosis and secondary pulmonary hypertension—both progressive conditions that severely scar the lungs—underwent successful robotic lung transplants at the hospital.
Given the complexity of the cases, which included pulmonary hypertension placing additional strain on the heart and lungs, the surgical team employed Veno-Arterial ECMO (Extracorporeal Membrane Oxygenation). This technique temporarily takes over the function of both the heart and lungs, ensuring patients' safety during the transplant.
The surgeries were made possible through the vital contributions of organ donor families, with Cleveland Clinic Abu Dhabi extending its gratitude to the HAYAT National Programme for Organ Donation and Transplantation, the Department of Health – Abu Dhabi, the Ministry of Health and Prevention (MOHAP), and the healthcare teams at donor hospitals.
Since the relaunch of its lung transplant programme in 2022, the hospital has performed over 60 lung transplants—more than any other facility in the Gulf.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CairoScene
2 days ago
- CairoScene
Gulf's First Robotic Lung Transplant Performed in Abu Dhabi
Two patients with progressive conditions underwent successful robotic lung transplants at the hospital. Jul 11, 2025 In a historic breakthrough for regional healthcare, Cleveland Clinic Abu Dhabi has become the first medical institution in the Gulf to perform a robotic lung transplant—making it just the fifth centre worldwide to do so. The landmark procedure marks a major advancement in the region's surgical capabilities. Two patients with idiopathic pulmonary fibrosis and secondary pulmonary hypertension—both progressive conditions that severely scar the lungs—underwent successful robotic lung transplants at the hospital. Given the complexity of the cases, which included pulmonary hypertension placing additional strain on the heart and lungs, the surgical team employed Veno-Arterial ECMO (Extracorporeal Membrane Oxygenation). This technique temporarily takes over the function of both the heart and lungs, ensuring patients' safety during the transplant. The surgeries were made possible through the vital contributions of organ donor families, with Cleveland Clinic Abu Dhabi extending its gratitude to the HAYAT National Programme for Organ Donation and Transplantation, the Department of Health – Abu Dhabi, the Ministry of Health and Prevention (MOHAP), and the healthcare teams at donor hospitals. Since the relaunch of its lung transplant programme in 2022, the hospital has performed over 60 lung transplants—more than any other facility in the Gulf.
Mid East Info
21-06-2025
- Mid East Info
The Department of Health – Abu Dhabi and Abbott Unite to Manufacture Pharmaceuticals Locally in Abu Dhabi - Middle East Business News and Information
During BIO International Convention in Boston USA, the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Abbott, the global healthcare leader, entered a landmark partnership to localise manufacturing of pharmaceuticals in Abu Dhabi and advance digital health solutions. Leveraging Abu Dhabi's advanced life sciences infrastructure, this milestone reflects the emirate's proactive preparedness to reduce dependency on imports, strengthen supply chain resilience, and foster a sustainable, self-sufficient healthcare ecosystem. H.E. Dr. Noura Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, said: 'Following the recent launch of the Health, Endurance, Longevity and Medicine (HELM) Cluster in Abu Dhabi, the emirate proved to be equipped with a holistic, integrated infrastructure that fosters local manufacturing and R&D, positioning it as a regional healthcare gateway and leader in life sciences. By integrating our strategic vision with Abbott's expertise, we aim to accelerate the development and deployment of innovative healthcare products and solutions, reducing time-to-market, improving healthcare outcomes, and ensuring that breakthrough therapies reach patients faster. This approach positions Abu Dhabi as a regional leader in fostering an agile, innovation-driven healthcare ecosystem that directly translates scientific advancements into tangible benefits for our community.' The strategic collaboration outlines a comprehensive plan focusing on four key pillars including localisation of Abbott's pharmaceutical portfolio, biosimilar development, digital transformation through electronic patient information leaflets, and a robust education and workforce development initiative. Mazen Bachir, Regional Director for Abbott's established pharmaceuticals business in the Gulf, Emerging Markets and Levant said: 'Abbott is proud to announce a strategic collaboration with the Department of Health – Abu Dhabi, aimed at advancing healthcare resilience and innovation in Abu Dhabi. Building on Abbott's long-standing commitment to the UAE's healthcare system, this partnership will focus on localising existing pharmaceutical products, and jointly exploring the development of biosimilars, supported by regulatory alignment. The collaboration also includes initiatives to digitise life science product information through electronic leaflets in alignment with the UAE's digital health strategy. Another key component of this collaboration is the development of education programs to build local capabilities. Additionally, Abbott and the Department of Health will evaluate opportunities for joint research and development to strengthen long-term healthcare sustainability in the UAE.' Led by DoH, a high-level delegation has embarked on a strategic mission to the United States from June 15 to 21, 2025. The delegation will conduct over 20 strategic meetings and visits with public and private sector leaders across the U.S., aimed at knowledge exchange, investment opportunities and the signing of new agreements that accelerate the adoption of advanced health solutions.
Mid East Info
15-06-2025
- Mid East Info
Abu Dhabi Reinforces Global Leadership in Healthcare Innovation with High-Level U.S. Visit - Middle East Business News and Information
Strategic mission to the U.S. aims to strengthen partnerships and showcase Abu Dhabi's excellence in life sciences and precision medicine Abu Dhabi, United Arab Emirates – June 2025: A high-level delegation led by the Department of Health – Abu Dhabi (DoH), is set to embark on a strategic mission to the United States from June 14 to 21, 2025. The visit reaffirms Abu Dhabi's global leadership in healthcare innovation and reflects its broader vision for healthcare transformation—driven by innovation, investment, and a deep commitment to global collaboration. The delegation will visit key U.S. cities including Boston, Washington D.C., and Philadelphia, in parallel with Abu Dhabi's participation at BIO International Convention 2025 , one of the world's foremost biotechnology events. The visit will spotlight the Emirate's achievements in AI, digital health, genomics, and clinical research and showcase Abu Dhabi's Health, Endurance, Longevity and Medicine (HELM) Life Science Cluster, while promoting long-term strategic partnerships with government entities, research institutions, and global innovators. H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, stated: 'This mission reflects our commitment to shaping the future of health through collaboration, innovation, and shared purpose. Our vision is to build a health system that predicts, prevents, acts to restore, and acts to cure, therefore ensuring better outcomes for our communities and beyond. This can only be achieved through meaningful partnerships and a shared ambition to improve lives. We are proud to join our partners in the United States to explore new opportunities that advance healthcare, both in the UAE and globally.' The delegation will conduct over 20 strategic meetings and visits with public and private sector leaders across the U.S., aimed at knowledge exchange, investment opportunities, and the signing of new agreements that accelerate the adoption of advanced health solutions. Representing Abu Dhabi's innovation ecosystem, the delegation includes key stakeholders such as the Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, PureHealth, and Etihad Cargo. Abu Dhabi continues to lead the region in genomics through the Emirati Genome Programme, which has successfully sequenced over 800,000 samples, creating one of the most advanced national genomic databases. The Emirate is also home to more than 90 licensed research centers and 30+ ongoing clinical trials in areas such as oncology, rare diseases, and chronic conditions. Advanced data platforms such as Malaffi, which securely store over 5 million patient records—enable AI-powered insights and real-world evidence, while national initiatives like the Golden Visa program are cultivating a global workforce and have granted over 2,000 long-term visas for researchers and healthcare professionals from around the world.
